LILAC INSIGHTS PRIVATE LIMITED™
Office No-301 & 302, Rupa Solitaire Premises C. S. Ltd.
Sector-1, Building No-A-1, Millennium Business Park,
MIDC Mahape, Navi Mumbai-400710
T:+912241841438 F:+912241841448
CIN : U85191MH2011PTC217513

To: **Narayana Hrudayalaya Limited** **Report of: DUNDAPPA YALLAPPA MAMBRI**	Sample ID : 2410005293 Patient ID : 10023139691 Collected on : 13-02-2024 Received on : 14-02-2024 Reported on : 20-02-2024 **Ref By: Dr. Sangeeta**

MSI BY IHC REPORT

Patient Name: Dundappa Yallappa Mambri	**Age: 59 Yrs/ Gender: Male**
Physician Name: Dr. Sangeeta	**Specimen Type: FFPE BLOCK**

Specimen:
Hemicolectomy (Blocks for MSI by IHC). .

Clinical Diagnosis:
Moderately differentiated adenocarcinoma.

Gross Description:
1 Block is received, labelled as "359/24 B" and relablled as "H24106730".

Microscopic Description:
MLH1 - Intact nuclear expression.
PMS2 - Intact nuclear expression.
MSH2 - Intact nuclear expression.
MSH6 - Intact nuclear expression.

LILAC INSIGHTS PRIVATE LIMITED™
Office No-301 & 302, Rupa Solitaire Premises C. S. Ltd.
Sector-1, Building No-A-1, Millennium Business Park,
MIDC Mahape, Navi Mumbai-400710
T:+912241841438 F:+912241841448
CIN : U85191MH2011PTC217513

Appropriate internal controls are positive.
IHC staining is suboptimal due to processing and fixation artefacts. Done twice.

Diagnosis:
This tumour is proficient for MMR proteins.

Interpretation, CAP, October 2015.

MLH-1	PMS-2	MSH-2	MSH-6	IHC interpretation to be confirmed by genetic testing *
+	+	+	+	low probability of microsatellite instability-high (MSI-H)
-	-	+	+	testing for methylation of the MLH1 promoter and/or mutation of BRAF is indicated **
+	+	-	-	MSH-2/MSH-6 germline mutation (HNPCC)
+	-	+	+	PMS-2 germline mutation (HNPCC)
+	+	+	-	MSH-6 germline mutation (HNPCC)
HNPCC, hereditary nonpolyposis colorectal carcinoma.				

*Sequencing and/or large deletion/duplication testing of germline MLH-1 or PMS-2 or MSHG-2 or MSH-6 indicated corresponding to IHC results.

** (the presence of BRAF V600E mutation and/or MLH1 methylation suggests that the tumor is sporadic andgermline evaluation is probably not indicated.
Absence of both MLH1 methylation and of BRAF V600E mutation suggests the possibility of Lynch syndrome.

There are exceptions to the above IHC interpretations. These results should not be considered in isolation, andclinical correlation with genetic counseling is recommended to assess the need for germline testing.



DR. RADHIKA MHATRE
MD, DM (NEUROPATH)
NIMHANS
Reg. No.- G-83742

END OF REPORT